180 related articles for article (PubMed ID: 18303488)
1. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial.
Lerner V; Miodownik C; Gibel A; Kovalyonok E; Shleifer T; Goodman AB; Ritsner MS
Clin Neuropharmacol; 2008; 31(1):25-33. PubMed ID: 18303488
[TBL] [Abstract][Full Text] [Related]
2. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
[TBL] [Abstract][Full Text] [Related]
3. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
4. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
[TBL] [Abstract][Full Text] [Related]
5. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Gibel A; Ritsner MS
Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
[TBL] [Abstract][Full Text] [Related]
6. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
7. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
[TBL] [Abstract][Full Text] [Related]
8. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial.
Berk M; Copolov D; Dean O; Lu K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Judd F; Katz F; Katz P; Ording-Jespersen S; Little J; Conus P; Cuenod M; Do KQ; Bush AI
Biol Psychiatry; 2008 Sep; 64(5):361-8. PubMed ID: 18436195
[TBL] [Abstract][Full Text] [Related]
9. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
10. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
Chen ZH; Wang GH; Wang XP; Chen RY; Wang HL; Yang MH; Huo YX; Mei HB
Hum Psychopharmacol; 2008 Aug; 23(6):465-70. PubMed ID: 18536066
[TBL] [Abstract][Full Text] [Related]
11. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.
Tamrakar SM; Nepal MK; Koirala NR; Sharma VD; Gurung CK; Adhikari SR
Kathmandu Univ Med J (KUMJ); 2006; 4(2):152-60. PubMed ID: 18603890
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
Potkin SG; Litman RE; Torres R; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S4-11. PubMed ID: 18334911
[TBL] [Abstract][Full Text] [Related]
13. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
[TBL] [Abstract][Full Text] [Related]
14. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
Lee SW; Lee JG; Lee BJ; Kim YH
Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
Lee KU; Jeon YW; Lee HK; Jun TY
Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
[TBL] [Abstract][Full Text] [Related]
16. Shiatsu as an adjuvant therapy for schizophrenia: an open-label pilot study.
Lichtenberg P; Vass A; Ptaya H; Edelman S; Heresco-Levy U
Altern Ther Health Med; 2009; 15(5):44-6. PubMed ID: 19771930
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
[TBL] [Abstract][Full Text] [Related]
18. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine.
Delle Chiaie R; Salviati M; Fiorentini S; Biondi M
Exp Clin Psychopharmacol; 2007 Dec; 15(6):563-8. PubMed ID: 18179309
[TBL] [Abstract][Full Text] [Related]
19. Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study.
Levin FR; Evans SM; Coomaraswammy S; Collins ED; Regent N; Kleber HD
Am J Drug Alcohol Abuse; 1998 Aug; 24(3):343-60. PubMed ID: 9741939
[TBL] [Abstract][Full Text] [Related]
20. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
